Home > Back to Publisher > Report Information

The World Market for Anti-Infectives, Volume I: Antifungals

Kalorama Information
April 1, 2005
118 Pages - SKU: KLI1077787

Abstract Table of Contents Search inside this report Related Reports Buy by the Section

Countries covered: Global

The World Market for Anti-Infectives, Volume I: Antifungals

In the past 100 years, there has been a steady increase in the incidence of serious secondary systemic fungal infections. One of the factors aiding the spread of fungal disease has been the widespread use of broad-spectrum antibiotics, which eliminate or decrease the non-pathogenic bacterial populations that normally compete with fungi. Another has been the vast increase in populations with with compromised immune response (caused by AIDS or by the action of immunosuppressant drugs or cancer chemotherapy agents).

In addition to rising prevalence, new technology in anti-fungal agent discovery has been brisk and innovative approaches have made anti-fungal drug development a diverse and competitive field.

This volume of Kalorama Information’s completely updated series on the World Market for Anti-Infectives focuses on two segments of anti-fungal treatment: systemic and topical. The report covers both currently marketed and late stage development anti-fungal products in detail.

The report includes statistical information for fungal infections by type worldwide, with special emphasis on the U.S. market. The market segments provide an overview, description of products on the market, description of products in development, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry.

Revenues for each segment were generated using dollar and unit sales for each product. All market data pertain to the world market at the manufacturers’ level. The base year for data was 2004. Historical data are provided for the years 2002 and 2003, with forecast data provided for 2005 through 2009. Compound annual growth rates (CAGRs) are provided for the 2002-2004, 2004-2009, and 2002-2009 periods for each industry segment covered. Competitive analysis is provided for the year 2004. The forecasted market analysis for 2005-2009 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

Chapter One: Executive Summary

Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting the Market
Leading Competitors

Chapter Two: Introduction

Fungal Infections
- Superficial
- Systemic
  - Histoplasmosis
  - Coccidioidomycosis
  - Blastomycosis
Demographics and Statistics

Chapter Three: Systemic Antifungal Drug

Overview:
Description of Products
- Allylamines
  - Terbinafine (Lamisil, Novartis)
- Azoles
  - Fluconazole (Diflucan, Pfizer)
  - Ketoconazole (Nizoral, Johnson & Johnson)
  - Miconazole (Monistat, Johnson & Johnson)
  - Itraconazole (Sporanox, Johnson & Johnson)
- Polyene Macrolides
  - Amphotericin B
  - Nystatin (Mycostatin, Westwood Squibb)
  - Griseofluvin (Fulvicin, Schering)
- Miscellaneous Antifungals
  - Flucytosine (Ancobon, ICN)
  - Echinocandins
  - Caspofungin (Cancidas for Injection, Merck)
Research and Development
Market Size and Growth
Competitive Analysis

Chapter Four: Topical Antifungal Drugs

Overview
Description of Products
- Allylamines
  - Naftifine (Naftin, Allergan)
  - Terbinafine (Lamisil, Novartis)
  - Butenafine (Mentax, Bertek)
  - Azoles
    - Miconazole (Monistat-Derm, OrthoDermatological)
    - Clotrimazole (Mycelex, Bayer; Lotrimin, Schering)
    - Ketoconazole (Nizoral, J&J)
    - Oxiconazole (Oxistat, GlaxoSmithKline/Elan)
    - Econazole (Spectazole, Ortho Dermatological)
    - Sulconazole (Exelderm, Westwood-Squibb)
    - Terconazole (Terazol, Ortho Dermatological)
    - Polyene Macrolides
      - Nystatin (Mycostatin, Westwood Squibb)
      - Miscellaneous Antifungals
        Ciclopirox (Penlac, Sanofi-Aventis/Dermik)
        Selenium sulfide (Selsun, Ross)
        Tolnaftate (Tinactin, Alpharma)
        Amorolfine (Loceryl, Roche)
    - Research and Development
    - Market Size and Growth
    - Competitive Analysis

Chapter Five: Issues and Trends

Expanded Use of Azoles
Drug Resistance and Interactions
Standardized Susceptibility Testing
Generic Impact and Availability
Importance of Drug Delivery
Fungal Vaccine Development
Rx-to-OTC Switches
Antifungal Proteins
Addressing the Unmet Need of the Antifungal Treatment Market
Tarmogen Technology

Chapter Six: Market Summary

Total Market Size and Forecast

chapter Seven: Company Profiles

Introduction
Bayer AG
Dermik Laboratories, Inc.
Enzon Pharmaceuticals, Inc.
Fujisawa Pharmaceutical Company, Ltd.
Johnson & Johnson Group
Merck & Company, Inc.
Novartis Pharmaceuticals Corporation
Pfizer, Inc.
Schering-Plough Corporation

Appendix: Company Directory
List of Exhibits
Chapter One: Executive Summary

Table 1-1: The Total World Market for Antifungal Drugs 2002-2009
Figure 1-1: The World Market for Antifungal Drugs 2002-2009

Chapter Two: Introduction

Table 2-1: Estimated World and U.S. Incidence of Fungal Infections
Figure 2-1: Estimated World and U.S. Incidence of Leading Fungal Infections
Table 2-2: World Population by Selected Geographical Region, 2004-2050
Figure 2-2: World Population by Selected Geographical Region, 2003-2050
Table 2-3: Estimated World Population by Age and Geographical Region, 2004
Figure 2-3: Estimated World Population by Age and Geographical Region, 2004

Chapter Three: Systemic Antifungal Drug

Table 3-1: Currently Available Systemic Antifungal Agents (Type, Brand, and Manufacturer)
Table 3-2: Systemic Antifungal Drugs in Development
Table 3-3: The Market for Systemic Antifungal Drugs 2002-2009
Figure 3-1: Systemic Antifungal Drug Market 2002-2009
Table 3-4: Systemic Antifungal Drug Market by Product Type (Allylamines, Azoles, Polyene Macrolides, and Others) 2002-2009
Figure 3-2: Systemic Antifungal Drug Market Revenues and Distribution by Product Type, 2002-2009
Figure 3-3: Systemic Antifungal Drug Market Share of Revenues by Product Type 2002-2009
Figure 3-4: Systemic Antifungal Drug Market Share by Product Type 2004 and 2009
Table 3-5: Systemic Antifungal Drug Market Estimated Products Sales by Infection Type, 2004
Figure 3-5: Systemic Antifungal Drug Market Market Share by Infection Type, 2004
Table 3-6: Systemic Antifungal Drug Market Estimated Products Sales by Geographic Region, 2004
Figure 3-6: Systemic Antifungal Drug Market Market Share by Geographic Region, 2004
Table 3-7: Systemic Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2004
Figure 3-7: Systemic Antifungal Drug Market Estimated Market Share by Leading Suppliers 2004
Table 3-8: Systemic Antifungal Drug Market Estimated Sales of Top Antifungal Products 2004
Figure 3-8: Systemic Antifungal Drug Market Estimated Market Share of Top Antifungal Products, 2004

Chapter Four: Topical Antifungal Drugs

Table 4-1: Currently Available Topical Antifungal Agents (Type, Brand, and Manufacturer)
Table 4-2: Topical Antifungal Drugs in Development
Table 4-3: The Market for Topical Antifungal Drugs 2002-2009
Figure 4-1: Topical Antifungal Drug Market 2002-2009
Table 4-4: Topical Antifungal Drug Market by Product Type (Allylamines, Azoles, Polyene Macrolides, and Others) 2002-2009
Figure 4-2: Topical Antifungal Drug Market Revenues and Distribution by Product Type 2002-2009
Figure 4-3: Topical Antifungal Drug Market Share of Revenues by Product Type 2002-2009
Figure 4-4: Topical Antifungal Drug Market Share by Product Type 2004 and 2009
Table 4-5: Topical Antifungal Drug Market Estimated Products Sales by Infection Type, 2004
Figure 4-5: Topical Antifungal Drug Market Market Share by Infection Type, 2004
Table 4-6: Topical Antifungal Drug Market Estimated Products Sales by Geographic Region, 2004
Figure 4-6: Topical Antifungal Drug Market Market Share by Geographic Region, 2004
Table 4-7: Topical Antifungal Drug Market Estimated Revenues and Market Share of Leading Suppliers 2004
Figure 4-7: Topical Antifungal Drug Market Estimated Market Share by Leading Suppliers 2004
Table 4-8: Topical Antifungal Drug Market Estimated Sales of Top Antifungal Products 2004
Figure 4-8: Topical Systemic Antifungal Drug Market
Estimated Market Share of Top Antifungal Products, 2004

Chapter Five: Issues and Trends

Table 5-1: Selected Antifungal Rx-to-OTC Switches
Table 5-2: Selected Potential Prescription Dermatological Rx-to-OTC Switches

Chapter Six: Market Summary

Table 6-1: The World Market for Antifungal Drugs 2002-2009
Figure 6-1: The World Market for Antifungal Drugs 2002-2009
Table 6-2: Topical Antifungal Drug Market by Type (Topical vs Systemic) 2002-2009
Figure 6-2: The World Market for Antifungal Drugs Revenues by Type (Systemic vs Topical) 2002-2009

More Global Infectious Diseases Reports

2012 World Infectious Disease Testing Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country by Venture Planning Group
This report provides a worldwide overview of the infectious disease testing market environment, structure, size and growth. Includes estimates of the number of laboratories ...

2012 Global Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies by Venture Planning Group
The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers ...

Global Infectious Disease Treatment Market 2011-2014 by Infiniti Research Limited
TechNavio’s analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 8.1 percent over the period 2011–2014. One of the key ...

World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections) by Kalorama Information
This Kalorama Information report – The World Market for Anti-Infectives - focuses on three key segments of treatment: Antifungals (Allylamines, Azoles, ...

Future Infectious Disease Testing Market: Growth Opportunities, Business Strategies, Market Entry Barriers and Risks by Venture Planning Group
The report identifies the major opportunities for infectious disease testing instrumentation, reagent kits/test panels, consumables, as well as IT and auxiliary products; proposes design criteria ...

See all reports like this >>

The World Market for Anti-Infectives, Volume I: Antifungals

Share this report

Other tasks

Research Assistance

Related Markets

Infectious Diseases Reports

Free Alert Me service